-

Leslie's, Inc. (LESL) Class Action Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Leslie's, Inc. Securities Fraud Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons or entities who purchased Leslie's, Inc. (NASADAQ: LESL) common stock between February 5, 2021 and July 13, 2023. Leslie’s provides pool supplies and related equipment to end consumers, both residential and professional.

For more information, submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What is this Case About: Leslie's, Inc. (LESL) Failed to Disclose that its Sales Growth was Based on Artificial Demand and Excess Panic Buying

According to the complaint, during the class period, defendants failed to disclose to investors that: (1) the Company’s growth was caused by customers over purchasing products to stockpile in case of a chemical shortage; (2) such sales inflated revenues and earnings and were not indicative of durable and sustainable demand or financial growth; (3) the Company took advantage of chemical shortages by urging customers to stock up on the products because Leslie’s could not “guarantee availability” of chemicals in the future; and (4) any slowdown in sales was not a normalization of past seasonality, but was due to the prior excess stockpiling.

Plaintiff alleges that on July 13, 2023, Leslie's pre-released preliminary results for the third quarter of 2023 revealing that sales in the third quarter of 2023 had declined by 12%, the Company’s earnings per share for the quarter was 42% below analysts’ estimates, and EBITDA was now between $124 to $128 million, below the prior forecast of $197 million. Additionally, after reaffirming its fiscal 2023 guidance the previous two quarters, Leslie’s slashed its financial outlook for the remainder of the year. As an explanation, the Company revealed that “consumers entered the pool season with a greater than normal amount of chemicals leftover from last year,” resulting in reduced purchasing. In addition, as part of this pre-release and the sudden drop in guidance, Leslie’s announced that its Chief Financial Officer Steven M. Weddell would be stepping down from his post effective August 7, 2023.

On this news, Leslie’s stock price fell more than 29%, from a closing price of $9.52 per share on July 13, 2023, to a closing price of $6.70 per share on July 14, 2023, and continued to fall another 18% the next trading day to close at $5.46 per share on July 17, 2023.

What Now: Similarly situated shareholders may be eligible to participate in the class action against Leslie's, Inc. Shareholders who want to act as lead plaintiff for the class must file their motion for lead plaintiff by November 7, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against Leslie's, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:LESL

Release Summary
Leslie's, Inc. (LESL) Failed to Disclose that its Sales Growth was Based on Artificial Demand and Excess Panic Buying
Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Franklin BSP Realty Trust, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Franklin BSP Realty Trust, Inc. (NYSE: FBRT) securities between November 5, 2024 and February 11, 2026. FBRT is a real estate investment trust that "originates, acquires and manages a diversified portfolio of commercial real estate debt secured by properties located in the United States." For more information, submit a form, email attorney Aar...

Investor Notice: Robbins LLP Informs Investors of the Snowflake Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Snowflake Inc. (NYSE: SNOW) Class A common stock between June 27, 2023 and February 28, 2024. Snowflake is a software company that provides cloud data storage that enables customers to consolidate data onto data-driven applications and share data for the purpose of running analytics and other processes. For more information, submit a form, ema...

Investor Notice: Robbins LLP Informs Investors of the Class Action Lawsuit on Behalf of Zynex, Inc. Stockholders

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Zynex, Inc. (NASDAQ: ZYKIQ) securities between February 25, 2021 and December 15, 2025. Zynex is a medical device manufacturer that produces and markets electrotherapy devices for use in pain management, physical rehabilitation, neurological diagnosis, and cardiac monitoring. For more information, submit a form, email attorney Aaron Dumas, Jr....
Back to Newsroom